We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+15.19%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.5B
AUM Growth
+$190M
Cap. Flow
+$57.5M
Cap. Flow %
3.83%
Top 10 Hldgs %
78.34%
Holding
38
New
–
Increased
10
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$33.3M
2
CDXS icon
Codexis
CDXS
+$18.9M
3
LAB icon
Standard BioTools
LAB
+$14.3M
4
GH icon
Guardant Health
GH
+$7.08M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$6.71M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$12.7M
2
PLRX icon
Pliant Therapeutics
PLRX
+$10.8M
3
DNLI icon
Denali Therapeutics
DNLI
+$7.68M
4
VCYT icon
Veracyte
VCYT
+$5.39M
5
KYTX icon
Kyverna Therapeutics
KYTX
+$4.31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTNM
26
Contineum Therapeutics
CTNM
$599M
$5.68M 0.38%
296,666
– –
IPSC icon
27
Century Therapeutics
IPSC
$357M
$5.49M 0.37%
3,212,316
-1,978,190
-38% -$3.88M
GRAL
28
GRAIL Inc
GRAL
$3.02B
$4.82M 0.32%
350,000
+270,001
+338% +$4.09M
ABSI icon
29
Absci
ABSI
$1.34B
$3.72M 0.25%
973,260
– –
PACB icon
30
Pacific Biosciences
PACB
$441M
$1.76M 0.12%
1,035,859
– –
PRME icon
31
Prime Medicine
PRME
$508M
$1.42M 0.09%
367,175
– –
EXAI
32
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.04M 0.07%
213,900
– –
GLUE icon
33
Monte Rosa Therapeutics
GLUE
$1.3B
$456K 0.03%
86,014
-175,000
-67% -$883K
DNA icon
34
Ginkgo Bioworks
DNA
$584M
$297K 0.02%
36,493
-1
-0% -$10
KRON
35
DELISTED
Kronos Bio
KRON
$124K 0.01%
123,839
– –
PLRX icon
36
Pliant Therapeutics
PLRX
$64.4M
– –
-1,000,000
Closed -$10.8M
KYTX icon
37
Kyverna Therapeutics
KYTX
$457M
– –
-575,000
Closed -$4.31M
OMIC
38
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
– –
-44,129
Closed -$373K
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Casdin Capital held 38 positions worth $1.5B, up 15% from $1.31B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Casdin Capital deployed $57.5M of net new capital in Q3 2024, adding to 10 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $12.7M trimmed.

  • Casdin Capital added most to Illumina in Q3 2024, an estimated $33.3M increase.
  • Casdin Capital's biggest Q3 2024 reduction was Revolution Medicines, cutting an estimated $12.7M.
  • Casdin Capital fully exited Pliant Therapeutics in Q3 2024, selling an estimated $10.8M.
  • Casdin Capital's ten largest holdings make up 78% of its $1.5B portfolio in Q3 2024.
  • Casdin Capital opened 0 new positions and closed 3 in Q3 2024.
  • Casdin Capital's portfolio value rose 15% quarter-over-quarter to $1.5B.

Based on Casdin Capital's 13F filing for Q3 2024, filed 14 Nov 2024.